Pre-market hot trades in US stocks: Visionary pre-market down 9.09%; Grayscale Ethereum Staking ETF pre-market down 4.94%

Pre-market Hot Trades in US Stocks Visionary, down 9.09% in pre-market, with no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Grayscale Ethereum Staking ETF down 4.94% in pre-market. Based on recent key news: On May 16, analysts pointed out that Ethereum faces downward pressure due to increased exchange supply and decreased ETF demand, which could lead to a significant drop in ETH value to $1,700. This news raised market concerns, leading to a decline in ETF prices. On May 16, CryptoQuant data showed an increase in Ethereum inflows to exchanges, and spot ETFs experienced outflows totaling $190 million over four consecutive days. This liquidity change intensified negative market expectations for Ethereum prices, pushing ETF prices down. On May 18, Harvard University reduced its Bitcoin ETF holdings by 43% and sold all its Ethereum ETF holdings. This move indicates a weakening of institutional investors' confidence in the cryptocurrency market, further impacting ETF prices. Sentiment in the crypto market is pessimistic, with panic selling intensifying. Top Gainers in Pre-market US Stocks Sunshine Biopharma, up 195.67% in pre-market, with no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Huachen AI Parking Management Tech, up 89.89% in pre-market, with no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. GeoVax Labs up 88.62% in pre-market. Based on recent key news: On May 14, GeoVax Labs announced its strategic focus, emphasizing prioritizing capital and operations on the GEO-MVA project while maintaining Gedeptin development as an important long-term option in combination immunotherapy. This strategic adjustment is considered the main factor driving the stock price up. Source: SEC announcement On May 14, GeoVax Labs released original content through the EDGAR system, detailing its strategic adjustments and future development directions. This disclosure increased market confidence in the company's future growth potential, further driving the stock price up. Source: SEC announcement On May 14, the market interpreted GeoVax Labs' strategic adjustments as a positive signal for the company's future development, leading investors to express optimism about its long-term potential in combination immunotherapy, resulting in a significant stock price increase. Source: SEC announcement. The biotechnology industry has recently performed strongly, with significant capital inflows